{
  "url": "https://finance.yahoo.com/news/viral-sensitizers-global-strategic-research-080700248.html?_guc_consent_skip=1754986644",
  "authorsByline": "Research and Markets",
  "articleId": "389f1cdf8e334275b8ac359d73fb8a47",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/globenewswire.com/f96b49a5aa2502a2558fa2bfbb767663",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-12T08:07:00+00:00",
  "addDate": "2025-08-12T08:20:57.443985+00:00",
  "refreshDate": "2025-08-12T08:20:57.443988+00:00",
  "score": 1.0,
  "title": "Viral Sensitizers Global Strategic Research Report 2025-2030",
  "description": "Market opportunities in the Viral Sensitizers sector include advancements in gene and cancer therapies, driven by the need for targeted treatments and overcoming drug resistance. Growth is propelled by biotechnological innovations, increased investment, and collaborations, with significant expansion expected in the U.S. and China markets. Viral Sensitizers Market Viral Sensitizers Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The \"Viral Sensitizers - Global Strategic Business Report\" has been",
  "content": "Market opportunities in the Viral Sensitizers sector include advancements in gene and cancer therapies, driven by the need for targeted treatments and overcoming drug resistance. Growth is propelled by biotechnological innovations, increased investment, and collaborations, with significant expansion expected in the U.S. and China markets. Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The \"Viral Sensitizers - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.\n\n\n\nThe global market for Viral Sensitizers was estimated at US$2.0 Billion in 2024 and is projected to reach US$3.9 Billion by 2030, growing at a CAGR of 12.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Viral Sensitizers market.\n\n\n\n \n\n\n\nViral sensitizers are compounds or agents that enhance a host cell's susceptibility to viral infection or increase the efficacy of viral replication in targeted therapies. While traditionally, the objective in virology has been to prevent infection, viral sensitizers are gaining attention for their role in therapeutic strategies such as viral gene therapy, oncolytic virotherapy, and vaccine development. In these contexts, sensitizing specific cells or tissues to viral vectors can improve the efficiency and precision of treatment delivery. What Is Driving the Global Interest and Market Growth for Viral Sensitizers?\n\n\n\nThe growth in the viral sensitizers market is driven by several factors closely linked to the evolution of biotechnology, unmet clinical needs, and increased research into viral therapies. One of the strongest drivers is the rising demand for targeted and personalized medicine, particularly in the treatment of cancers and genetic disorders where conventional therapies have limited success. As viral-based therapeutics gain regulatory approval and commercial traction, the need for complementary agents that can enhance their performance has become more pressing. Another important factor is the surge in investment from pharmaceutical and biotech companies in gene and cell therapy pipelines, many of which rely on viral vectors for delivery. These companies are actively seeking innovations that improve vector efficiency, tissue selectivity, and safety, all of which can be supported by the use of sensitizers. Additionally, the growing acceptance of oncolytic virotherapy and immunovirotherapy as viable treatment options has brought attention to the role of sensitizers in modulating tumor microenvironments and overcoming resistance. Advancements in clinical trial design and regulatory pathways are also enabling faster development and approval of these adjunctive technologies. Government-funded research initiatives and collaborations between academic institutions and industry players are further fueling innovation and expanding the potential applications of viral sensitizers.\n\nThe increasing understanding of viral pathogenesis and host cell biology is creating new opportunities to manipulate these interactions for therapeutic gain. Together, these trends are establishing viral sensitizers as a high-potential segment within the broader biomedical market, with growing importance in clinical research, drug development, and future healthcare strategies.\n\n\n\nHow Are Technological Advancements Reshaping the Development and Application of Viral Sensitizers?\n\n\n\nThe rapid progress in molecular biology, genetic engineering, and nanotechnology is significantly influencing the development of more sophisticated viral sensitizers. Modern research tools such as CRISPR-based gene editing and high-throughput screening have made it possible to identify and validate host cell factors that regulate viral entry, replication, and egress. These discoveries are leading to the design of sensitizers that can modulate specific cellular pathways to either upregulate viral receptors or temporarily suppress antiviral defenses, thereby enhancing the performance of viral-based therapies. Advances in nanoparticle delivery systems are also enabling the targeted transport of sensitizers directly to disease sites, minimizing systemic exposure and potential off-target effects. In parallel, bioinformatics and machine learning tools are being employed to predict cell-virus interactions and identify new sensitizer candidates with improved safety profiles. Researchers are also exploring combination therapies where sensitizers are co-administered with viral vectors to achieve synergistic effects, particularly in the treatment of aggressive cancers and genetic disorders. Additionally, synthetic biology is playing a pivotal role in designing viral vectors and sensitizers that can respond to environmental cues or specific cellular markers. These technological innovations are transforming viral sensitizers from experimental reagents into refined therapeutic tools, broadening their applicability and improving their integration into clinical practice. As these tools become more precise and customizable, the role of viral sensitizers in advanced biomedical applications is expected to grow significantly.\n\n\n\nWhy Are Viral Sensitizers Crucial in the Evolving Landscape of Cancer and Gene Therapies?\n\n\n\nAs the medical community continues to shift toward more personalized and targeted treatment modalities, viral sensitizers are emerging as essential components in the advancement of cancer and gene therapies. In oncology, the use of oncolytic viruses to destroy cancer cells relies heavily on the ability of these viruses to infiltrate and replicate selectively within tumor tissues. However, many tumors possess intrinsic resistance mechanisms that prevent viral entry or replication. Sensitizers are employed to modulate these mechanisms, either by downregulating host antiviral proteins or by upregulating viral receptors on the surface of cancer cells. This enhances the therapeutic index of the viral agent and allows for more efficient tumor targeting. In the field of gene therapy, where precision is critical, sensitizers can facilitate the delivery of viral vectors into difficult-to-transduce cells such as neurons, muscle fibers, or hematopoietic stem cells. Moreover, sensitizers can be fine-tuned to transiently alter the cellular environment, allowing optimal vector activity without long-term disruption of normal cellular functions. The ability to control where and when viruses act within the body offers a major advantage in minimizing side effects and enhancing treatment outcomes. Additionally, researchers are now exploring dual-function agents that act both as sensitizers and immune modulators, thereby boosting both viral efficacy and host immune responses. These developments underscore the central role of viral sensitizers in overcoming some of the key limitations faced in next-generation therapeutic approaches, particularly in complex diseases that require highly targeted intervention.\n\n\n\nReport Features:\n\u2022 Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.\n\u2022 In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.\n\u2022 Company Profiles: Coverage of players such as AbbVie, ALSTEM, Alnylam Pharmaceuticals, AstraZeneca, Bluebird Bio and more.\n\u2022 Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.\n\u2022 Market Growth: Understand the significant growth trajectory of the Antiviral Drug Development Application segment, which is expected to reach US$2.1 Billion by 2030 with a CAGR of a 10.9%. The Vaccine Development Application segment is also set to grow at 13.6% CAGR over the analysis period.\n\u2022 Regional Analysis: Gain insights into the U.S. market, estimated at $536.6 Million in 2024, and China, forecasted to grow at an impressive 16.3% CAGR to reach $818.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.\n\u2022 Breakthroughs in Immunotherapy Throw the Spotlight on the Role of Viral Sensitizers in Cancer Treatment\n\u2022 Expansion of mRNA and Viral Vector Platforms Strengthens the Case for Optimized Viral Sensitizers\n\u2022 Push Toward Personalized Medicine Enhances the Need for Precision Viral Sensitization Mechanisms\n\u2022 Adoption of Combination Therapies Drives Integration of Viral Sensitizers in Antiviral and Immunomodulatory Regimens\n\u2022 Increased Prevalence of Viral-Oncogenic Diseases Expands the Addressable Market for Therapeutic Sensitizers\n\u2022 Here's How Advancements in Viral Imaging and Biomarker Discovery Are Unlocking New Use Cases\n\u2022 Demand for Adjuvant Technologies in Vaccinology Bolsters Interest in Immune-Sensitizing Agents\n\u2022 Shifting Focus Toward Immune Priming in Early Infection Stages Opens Strategic Demand for Prophylactic Sensitizers For more information about this report visit https://www.researchandmarkets.com/r/a5hhwg About ResearchAndMarkets.com\n\nResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900",
  "medium": "Article",
  "links": [
    "https://www.researchandmarkets.com/reports/6107116/viral-sensitizers-global-strategic-business?utm_source=GNE&utm_medium=PressRelease&utm_code=pxvplv&utm_campaign=2083806+-+Viral+Sensitizers+Global+Strategic+Research+Report+2025-2030+%7c+Expansion+of+mRNA+and+Viral+Vector+Platforms+Strengthens+the+Case+for+Optimized+Viral+Sensitizers&utm_exec=chdomsai",
    "https://ml.globenewswire.com/Resource/Download/f52497b5-4131-43a8-8868-60851589d2a5"
  ],
  "labels": [
    {
      "name": "Roundup"
    },
    {
      "name": "Opinion"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Viral Sensitizers",
      "weight": 0.11054104
    },
    {
      "name": "Viral sensitizers",
      "weight": 0.11054104
    },
    {
      "name": "viral sensitizers",
      "weight": 0.11054104
    },
    {
      "name": "Optimized Viral Sensitizers",
      "weight": 0.10293772
    },
    {
      "name": "viral therapies",
      "weight": 0.09529341
    },
    {
      "name": "viral gene therapy",
      "weight": 0.09471987
    },
    {
      "name": "viral vectors",
      "weight": 0.09331321
    },
    {
      "name": "viral infection",
      "weight": 0.0875552
    },
    {
      "name": "viral replication",
      "weight": 0.08581025
    },
    {
      "name": "viral receptors",
      "weight": 0.08576414
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Business"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Other",
      "score": 0.9248046875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.92431640625
    },
    {
      "name": "/Business & Industrial/Advertising & Marketing/Marketing",
      "score": 0.728515625
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.71923828125
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.341796875
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.3251953125
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.322265625
    }
  ],
  "sentiment": {
    "positive": 0.62679094,
    "negative": 0.031512324,
    "neutral": 0.34169674
  },
  "summary": "The \"Viral Sensitizers - Global Strategic Business Report\" has been added to ResearchAndMarkets. The report provides a comprehensive analysis of the market trends, drivers, and forecasts for 2025-2030. It estimates that the global market for Viral Sensitives will reach US$3.9 billion by 2030, growing at a CAGR of 12.3% from 2024 to 2030. Factors driving this growth include advancements in gene and cancer therapies driven by the need for targeted treatments and overcoming drug resistance. Viral sensitizers are compounds or agents that enhance a host cell's susceptibility to viral infection or increase the efficacy of viral replication in targeted therapies. They are also gaining attention for their role in therapeutic strategies such as viral gene therapy, oncolytic virotherapy, and vaccine development. Drug and biotech companies are investing in innovative gene and cell therapy pipelines, many of which rely on viral vectors for delivery.",
  "shortSummary": "The Viral Sensitizers market, driven by advancements in biotechnology and cancer therapy, is expected to grow 12.3% annually to meet growing clinical needs.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "01505762b22b4224874b9c925533378f",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.researchandmarkets.com/reports/6107116/viral-sensitizers-global-strategic-business?utm_source=GNE&utm_medium=PressRelease&utm_code=pxvplv&utm_campaign=2083806+-+Viral+Sensitizers+Global+Strategic+Research+Report+2025-2030+%7c+Expansion+of+mRNA+and+Viral+Vector+Platforms+Strengthens+the+Case+for+Optimized+Viral+Sensitizers&utm_exec=chdomsai",
      "text": "The global market for Viral Sensitizers was estimated at US$2.0 Billion in 2024 and is projected to reach US$3.9 Billion by 2030, growing at a CAGR of 12.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Viral Sensitizers market.\nSegments: Application (Antiviral Drug Development Application, Vaccine Development Application, Oncolytic Viral Therapies Application); End-Use (Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use, Other End-Uses)\nGeographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.\nGlobal Viral Sensitizers Market - Key Trends & Drivers Summarized\nWhat Are Viral Sensitizers and Why Are They Gaining Attention in Modern Biomedical Research?\nViral sensitizers are compounds or agents that enhance a host cell's susceptibility to viral infection or increase the efficacy of viral replication in targeted therapies. While traditionally, the objective in virology has been to prevent infection, viral sensitizers are gaining attention for their role in therapeutic strategies such as viral gene therapy, oncolytic virotherapy, and vaccine development. In these contexts, sensitizing specific cells or tissues to viral vectors can improve the efficiency and precision of treatment delivery. For instance, in oncolytic virotherapy, where viruses are engineered to selectively infect and destroy cancer cells, sensitizers are used to enhance viral entry into malignant cells while sparing healthy tissues. This targeted approach has the potential to overcome limitations associated with drug resistance and tumor heterogeneity. In vaccine development, certain sensitizing agents help amplify the immune response by ensuring better viral uptake and antigen presentation. Additionally, viral sensitizers are increasingly being studied for their role in overcoming cellular defense mechanisms such as interferon responses, thereby optimizing viral replication for therapeutic benefit. As biotechnology advances, these compounds are being engineered for higher specificity, lower toxicity, and compatibility with diverse viral platforms. Their expanding role across therapeutic areas is attracting the interest of pharmaceutical companies and research institutions seeking more effective, cell-specific treatments, positioning viral sensitizers as a critical component of future medical interventions.How Are Technological Advancements Reshaping the Development and Application of Viral Sensitizers?\nThe rapid progress in molecular biology, genetic engineering, and nanotechnology is significantly influencing the development of more sophisticated viral sensitizers. Modern research tools such as CRISPR-based gene editing and high-throughput screening have made it possible to identify and validate host cell factors that regulate viral entry, replication, and egress. These discoveries are leading to the design of sensitizers that can modulate specific cellular pathways to either upregulate viral receptors or temporarily suppress antiviral defenses, thereby enhancing the performance of viral-based therapies. Advances in nanoparticle delivery systems are also enabling the targeted transport of sensitizers directly to disease sites, minimizing systemic exposure and potential off-target effects. In parallel, bioinformatics and machine learning tools are being employed to predict cell-virus interactions and identify new sensitizer candidates with improved safety profiles. Researchers are also exploring combination therapies where sensitizers are co-administered with viral vectors to achieve synergistic effects, particularly in the treatment of aggressive cancers and genetic disorders. Additionally, synthetic biology is playing a pivotal role in designing viral vectors and sensitizers that can respond to environmental cues or specific cellular markers. These technological innovations are transforming viral sensitizers from experimental reagents into refined therapeutic tools, broadening their applicability and improving their integration into clinical practice. As these tools become more precise and customizable, the role of viral sensitizers in advanced biomedical applications is expected to grow significantly.Why Are Viral Sensitizers Crucial in the Evolving Landscape of Cancer and Gene Therapies?\nAs the medical community continues to shift toward more personalized and targeted treatment modalities, viral sensitizers are emerging as essential components in the advancement of cancer and gene therapies. In oncology, the use of oncolytic viruses to destroy cancer cells relies heavily on the ability of these viruses to infiltrate and replicate selectively within tumor tissues. However, many tumors possess intrinsic resistance mechanisms that prevent viral entry or replication. Sensitizers are employed to modulate these mechanisms, either by downregulating host antiviral proteins or by upregulating viral receptors on the surface of cancer cells. This enhances the therapeutic index of the viral agent and allows for more efficient tumor targeting. In the field of gene therapy, where precision is critical, sensitizers can facilitate the delivery of viral vectors into difficult-to-transduce cells such as neurons, muscle fibers, or hematopoietic stem cells. Moreover, sensitizers can be fine-tuned to transiently alter the cellular environment, allowing optimal vector activity without long-term disruption of normal cellular functions. The ability to control where and when viruses act within the body offers a major advantage in minimizing side effects and enhancing treatment outcomes. Additionally, researchers are now exploring dual-function agents that act both as sensitizers and immune modulators, thereby boosting both viral efficacy and host immune responses. These developments underscore the central role of viral sensitizers in overcoming some of the key limitations faced in next-generation therapeutic approaches, particularly in complex diseases that require highly targeted intervention.What Is Driving the Global Interest and Market Growth for Viral Sensitizers?\nThe growth in the viral sensitizers market is driven by several factors closely linked to the evolution of biotechnology, unmet clinical needs, and increased research into viral therapies. One of the strongest drivers is the rising demand for targeted and personalized medicine, particularly in the treatment of cancers and genetic disorders where conventional therapies have limited success. As viral-based therapeutics gain regulatory approval and commercial traction, the need for complementary agents that can enhance their performance has become more pressing. Another important factor is the surge in investment from pharmaceutical and biotech companies in gene and cell therapy pipelines, many of which rely on viral vectors for delivery. These companies are actively seeking innovations that improve vector efficiency, tissue selectivity, and safety, all of which can be supported by the use of sensitizers. Additionally, the growing acceptance of oncolytic virotherapy and immunovirotherapy as viable treatment options has brought attention to the role of sensitizers in modulating tumor microenvironments and overcoming resistance. Advancements in clinical trial design and regulatory pathways are also enabling faster development and approval of these adjunctive technologies. Government-funded research initiatives and collaborations between academic institutions and industry players are further fueling innovation and expanding the potential applications of viral sensitizers. The increasing understanding of viral pathogenesis and host cell biology is creating new opportunities to manipulate these interactions for therapeutic gain. Together, these trends are establishing viral sensitizers as a high-potential segment within the broader biomedical market, with growing importance in clinical research, drug development, and future healthcare strategies.Scope Of Study:\nThe report analyzes the Viral Sensitizers market in terms of units by the following Segments, and Geographic Regions/Countries:Segments: Application (Antiviral Drug Development Application, Vaccine Development Application, Oncolytic Viral Therapies Application); End-Use (Pharmaceuticals Companies End-Use, Biotechnology Companies End-Use, Research Institutes End-Use, Other End-Uses)\nGeographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.\nKey Insights:\n- Market Growth: Understand the significant growth trajectory of the Antiviral Drug Development Application segment, which is expected to reach US$2.1 Billion by 2030 with a CAGR of a 10.9%. The Vaccine Development Application segment is also set to grow at 13.6% CAGR over the analysis period.\n- Regional Analysis: Gain insights into the U.S. market, estimated at $536.6 Million in 2024, and China, forecasted to grow at an impressive 16.3% CAGR to reach $818.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.\nWhy You Should Buy This Report:\n- Detailed Market Analysis: Access a thorough analysis of the Global Viral Sensitizers Market, covering all major geographic regions and market segments.\n- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.\n- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Sensitizers Market.\n- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.\nKey Questions Answered:\n- How is the Global Viral Sensitizers Market expected to evolve by 2030?\n- What are the main drivers and restraints affecting the market?\n- Which market segments will grow the most over the forecast period?\n- How will market shares for different regions and segments change by 2030?\n- Who are the leading players in the market, and what are their prospects?\nReport Features:\n- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.\n- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.\n- Company Profiles: Coverage of players such as AbbVie, ALSTEM, Alnylam Pharmaceuticals, AstraZeneca, Bluebird Bio and more.\n- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.\nSome of the 34 companies featured in this Viral Sensitizers market report include:\n- AbbVie\n- ALSTEM\n- Alnylam Pharmaceuticals\n- AstraZeneca\n- Bluebird Bio\n- Bristol-Myers Squibb\n- Cellectis\n- Gilead Sciences\n- Iovance Biotherapeutics\n- Johnson & Johnson\n- Merck & Co.\n- Moderna\n- Pfizer\n- Regeneron Pharmaceuticals\n- Roche (F. Hoffmann-La Roche)\n- Takara Bio\n- Thermo Fisher Scientific\n- Virica Biotech\n- Virongy Biosciences\n- FUJIFILM Irvine Scientific\nThis edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:\n- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.\n- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.\n- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.\n- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.\n- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.\n- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.\n- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.\nTable of Contents\nI. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION\n1. MARKET OVERVIEW\n3. MARKET TRENDS & DRIVERS\n4. GLOBAL MARKET PERSPECTIVE\nUNITED STATES\nJAPAN\nCHINA\nEUROPE\nFRANCE\nGERMANY\nUNITED KINGDOM\nASIA-PACIFIC\nAUSTRALIA\nINDIA\nLATIN AMERICA\nMIDDLE EAST\nAFRICA\nCompanies Mentioned (Partial List)\nA selection of companies mentioned in this report includes, but is not limited to:\n- AbbVie\n- ALSTEM\n- Alnylam Pharmaceuticals\n- AstraZeneca\n- Bluebird Bio\n- Bristol-Myers Squibb\n- Cellectis\n- Gilead Sciences\n- Iovance Biotherapeutics\n- Johnson & Johnson\n- Merck & Co.\n- Moderna\n- Pfizer\n- Regeneron Pharmaceuticals\n- Roche (F. Hoffmann-La Roche)\n- Takara Bio\n- Thermo Fisher Scientific\n- Virica Biotech\n- Virongy Biosciences\n- FUJIFILM Irvine Scientific\nTable Information\n| Report Attribute | Details |\n|---|---|\n| No. of Pages | 274 |\n| Published | August 2025 |\n| Forecast Period | 2024 - 2030 |\n| Estimated Market Value in 2024 | 2 Billion |\n| Forecasted Market Value by 2030 | 3.9 Billion |\n| Compound Annual Growth Rate | 12.3% |\n| Regions Covered | Global |"
    }
  ],
  "argos_summary": "The global market for Viral Sensitizers is projected to grow from US$2.0 billion in 2024 to US$3.9 billion by 2030, with a CAGR of 12.3%. This growth is driven by advancements in gene and cancer therapies, increased investment in biotechnology, and the rising demand for targeted treatments. Viral sensitizers enhance the efficacy of viral therapies by improving host cell susceptibility, making them crucial in the development of personalized medicine and overcoming drug resistance in complex diseases.",
  "argos_id": "XKY6D7K58"
}